<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789928</url>
  </required_header>
  <id_info>
    <org_study_id>2017-003</org_study_id>
    <nct_id>NCT04789928</nct_id>
  </id_info>
  <brief_title>Conservative Treatment of Catheter - Related Injections With Gentamicine/EDTA</brief_title>
  <acronym>CATH-GE</acronym>
  <official_title>Gentamicine-EDTA, a New Anti-biofilm Strategy for the Conservative Treatment of Catheter-related Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter-related infections are frequent. Treatment without catheter removal is difficult&#xD;
      because of the presence of biofilm. The association of gentamicin and EDTA is active in vitro&#xD;
      and in vivo against biofilms formed by Gram positive and Gram negative bacteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a pilot phase, non-comparative, non-randomized, multicentric study on 35 patients with uncomplicated LTIVC-related BSI and eligible for a conservative treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The clinical efficacy is assessed by the frequency of clinical and microbial cure after 30 days of follow-up after the end of treatment (D40)</measure>
    <time_frame>30 days of follow-up after the end of treatment (D40)</time_frame>
    <description>Resolution of clinical signs at the end of treatment (D6 if the patient already received 72h of a previous active lock before inclusion or D9 if he received a complete 10-day course of genta-EDTA-Na2 locks) and 30 days after completion of therapy (D40)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The long-term clinical efficacy is assessed by the frequency of microbial cure after 90 days of follow-up after the end of treatment.</measure>
    <time_frame>after 90 days of follow-up after the end of treatment (D100)</time_frame>
    <description>Absence of microbial relapse (BSI with the same microbial pathogen, i.e. same species and same antibiotic susceptibility pattern) between D6-D9 and D100;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Patients With Uncomplicated Long-term Central Venous Catheter-related Biofilm-related Infection</condition>
  <arm_group>
    <arm_group_label>Patients with uncomplicated LTIVC-related BSI and eligible</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included in this study will receive daily injection of genta-EDTA-Na2 lock associated with systemic antibiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicins-EDTA</intervention_name>
    <description>Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.</description>
    <arm_group_label>Patients with uncomplicated LTIVC-related BSI and eligible</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (≥18 year-old);&#xD;
&#xD;
          -  LTIVC in place (TIVAP or single-line tunnelled catheter);&#xD;
&#xD;
          -  LTIVC is functional (it is possible to inject an infusate, but also to draw blood from&#xD;
             the catheter);&#xD;
&#xD;
          -  LTIVC-related bloodstream infection defined by a positive qualitative paired blood&#xD;
             culture with a differential time to positivity ≥ 2 hours (meaning that the culture of&#xD;
             the blood drawn from the catheter is positive at least 2 hours before the culture of&#xD;
             the blood drawn from a peripheral vein);&#xD;
&#xD;
          -  Mono microbial infection caused by coagulase-negative staphylococci,&#xD;
             Enterobacteriaceae or Pseudomonas aeruginosa;&#xD;
&#xD;
          -  Bacterial strain is susceptible toward gentamicin;&#xD;
&#xD;
          -  Life expectancy ≥ 3 months;&#xD;
&#xD;
          -  Physician in charge of the patient agrees to perform a conservative treatment;&#xD;
&#xD;
          -  Calculated creatinine clearance ≥ 30 mL/min;&#xD;
&#xD;
          -  Patient's informed and written consent is collected.&#xD;
&#xD;
          -  For women of reproductive age: available beta-HCG dosage (with negative result) &lt; 72h.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any systemic complication (sepsis or septic shock), or local complications&#xD;
             (tunnel or port-pocket infection, thrombophlebitis, endocarditis, bone and joint&#xD;
             infections related to the LTIVC-related BSI);&#xD;
&#xD;
          -  Allergy toward aminoglycosides;&#xD;
&#xD;
          -  PICC-line or hemodialysis tunnelled catheter;&#xD;
&#xD;
          -  LTIVC removal is planned within the following 3 months or LTIVC is not required for&#xD;
             the management of the patient's underlying medical condition anymore;&#xD;
&#xD;
          -  Diagnosis of LTIVC-related bloodstream infection has been made more than 3 days ago&#xD;
             (e.g. &gt;72 hours between the day the first blood culture drawn from the LTIVC is&#xD;
             positive and the screening visit);&#xD;
&#xD;
          -  Systemic treatment of LTIVC-related bloodstream infection includes aminoglycosides&#xD;
             (defined as a recent (&lt;36 hours) or ongoing systemic injection of aminoglycosides)&#xD;
&#xD;
          -  Low blood ionized calcium level (&lt;1,15 mmol/L) before injecting the first dose of&#xD;
             genta-EDTA-Na2 lock;&#xD;
&#xD;
          -  Presence of prosthetic heart valve, pacemaker or implantable defibrillator;&#xD;
&#xD;
          -  The LTIVC has been inserted less than 14 days ago;&#xD;
&#xD;
          -  Available Count blood cells &lt; 72h with severe neutropenia (&lt;500 polymorphonuclear&#xD;
             cells/mm3);&#xD;
&#xD;
          -  Subject with infection caused by Staphylococcus aureus or Candida spp.;&#xD;
&#xD;
          -  The patient is not expected to remain in hospital for at least 7 days after inclusion&#xD;
&#xD;
          -  The administration of the lock according to the protocol (24 hours/day for 48 hours&#xD;
             and then at least 12 hours/24 hours for 5 to 8 days) is not possible.&#xD;
&#xD;
          -  Previous inclusion in a study or another therapeutic protocol requiring continuous use&#xD;
             of the catheter&#xD;
&#xD;
          -  Inability to perform a blood peripheral venous sampling&#xD;
&#xD;
          -  Pregnant and breastfeeding women,&#xD;
&#xD;
          -  Protected adults subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lebeaux</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou AP-HP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Lebeaux</last_name>
    <phone>+33 1 56 09 29 69</phone>
    <email>david.lebeaux@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandrine Fernandes Pellerin</last_name>
    <phone>+33145688179</phone>
    <email>cath-ge@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Lafaurie</last_name>
      <email>matthieu.lafaurie@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lebeaux</last_name>
      <phone>+33156092969</phone>
      <phone_ext>+33156092969</phone_ext>
      <email>david.lebeaux@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaël Lepeule</last_name>
      <phone>01 49 81 28 31</phone>
      <email>raphael.lepeule@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

